Business Context and Reporting Period
Company: CalciMedica, Inc. (Nasdaq: CALC)
Filing Type: Form 8-K (Current Report)
Date: October 30, 2024
Subject: Announcement of late-breaking positive data from the Phase 2b CARPO trial of Auxora for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS).
Key Financial Metrics
This filing is a current report regarding clinical trial results and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Results
The Company reported statistically significant efficacy and safety data from the Phase 2b CARPO trial (n=216). Key findings compared high/medium dose Auxora to low dose/placebo include:
- Severe Respiratory Failure: 0% incidence in high and medium dose groups vs. 8.3-8.5% in low dose/placebo groups (100% relative risk reduction, p=0.0027).
- Persistent Respiratory Failure: 1.9-8% incidence in high/medium dose groups vs. 10.4-17% in low dose/placebo groups (64.2% relative risk reduction, p=0.0476).
- Necrotizing Pancreatitis: 29.7% in high dose vs. 37.0% in placebo (approx. 20% relative risk reduction).
- Time to Discharge: Median time reduced by 15.0 hours for high dose patients (89.0 hours) compared to placebo (104.0 hours).
- Hospital Stay Duration: Combined high/medium dose patients showed reduced rates of stays longer than 7, 14, and 21 days compared to low dose/placebo.
- Win Ratio Analysis: High dose Auxora outperformed placebo with a stratified win ratio of 1.640 (p=0.0372).
- Safety: No drug-related treatment emergent serious adverse events (TESAEs) or deaths in the high dose group.
Guidance, Outlook, and Risks
Outlook: The Company is planning a Phase 3 program for Auxora in AP with SIRS. The design will be informed by CARPO results pending an end-of-Phase 2 meeting with the FDA.
Other Programs: Ongoing Phase 1/2 CRSPA trial for pediatric asparaginase-induced pancreatic toxicity and planned Phase 2 KOURAGE trial for acute kidney injury.
Risks: Forward-looking statements are subject to risks including regulatory approval uncertainty, clinical trial outcomes, capital needs, and market acceptance. The Company explicitly states it assumes no obligation to update these statements.
Investor Verification Checklist
- Verify the specific statistical significance (p-values) and confidence intervals for the reported relative risk reductions in the full clinical study report.
- Confirm the timeline and agenda for the planned end-of-Phase 2 meeting with the FDA.
- Review the Company's most recent Form 10-Q or 10-K for current cash runway and capital requirements to fund the planned Phase 3 trial.
- Assess the safety profile details regarding the trend of decreasing TESAE rates with increasing doses.
- Monitor the status of the CRSPA (pediatric) and KOURAGE (AKI) trials mentioned in the outlook.